Abstract
Background A variant strain of SARS-CoV-2, VOC202012/01, emerged in the UK in September, 2020. Its infectiousness was estimated as higher than that of the original strain.
Object We estimated the infectiousness of the variant strain of SARS-CoV-2 in comparison to that of the original strain under conditions prevailing in Japan.
Methods We estimated infectiousness through a simple susceptible–infected–recovered (SIR) model by strain. The study period was March 1–28, 2020. The information used for the study was available as of April 3, 2020.
Results The estimated reproduction number of the SARS-CoV-2 variant strain was 1.799; its 95% CI was [1.642, 1.938]. The onset date of the first case in Japan was estimated as December 4 ([November 16, December 14]), 2020. However, infectiousness of the original strain was estimated as 1.123 ([1.093, 1.166]).
Discussion and Conclusion We demonstrated that infectiousness increased by 0.684 or 60%, increasing from the original to the variant. That finding might be comparable to that of a study conducted in the UK. However, the difference must be monitored continuously and carefully.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All information used for this study has been published. There is therefore no ethical issue related to this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Ministry of Health, Labour and Welfare, Implementation rate and positive rate of screening test for the variant strain (mechanical estimation) preliminary figures. (in Japanese) World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update
https://www.mhlw.go.jp/content/000766381.pdf
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
